U.S. biomedical research is fracturing in public
Two separate threads today cover the same deterioration. Scientists were ejected from a diabetes conference for distributing journal reprints that criticized NIH leadership. A second piece, 'Misguided Misstatements Continue to Dismantle Biomedical Research,' adds more detail to the same story. HN commenters are not treating this as political noise; they are treating it as a structural crisis in how science gets funded and communicated in the U.S.
The comments are unusually direct. People are naming specific concerns about what happens to clinical trials, drug development pipelines, and academic research careers when the institutional environment becomes this hostile to dissent. The Biohub protein biology world model thread, which got almost no engagement despite being a major scientific result, sits in ironic contrast: genuinely exciting science is being ignored while the political dismantling of research infrastructure dominates attention.
This is not a founder issue in the traditional sense, but it is a talent pipeline and regulatory environment issue. Biotech and health tech founders are building on a research base that is under active political pressure.
So what?
Founders in biotech, health tech, and any field that depends on federally funded research should be mapping their dependencies on NIH-funded science now. The pipeline of academic research that feeds product development is being disrupted in ways that will take years to show up as missing breakthroughs. If your product roadmap assumes a steady stream of published research, that assumption deserves a stress test.
Read these
Scientists ejected from diabetes conference for distributing journal reprints
Misguided Misstatements Continue to Dismantle Biomedical Research in the U.S.
Biohub releases a world model of protein biology